Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced November 15, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML September 19, 2023
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML August 16, 2023
EMA Approves Clinical Trial Application (CTA) for AVC-201 for the Treatment of R/R AML and other CD123 Hematological Malignancies August 2, 2023
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML July 27, 2023
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs for Genetic Diseases, AML and MDS July 5, 2023
First Patient Dosed in Ph 2 IMpress Trial of Imetelstat in Patients with R/R AML or Higher Risk MDS June 21, 2023
Updated clinical data from Ph 1/2 KOMET-001 trial of ziftomenib in patients with heavily pretreated and co-mutated R/R NPM1-mutant AML announced June 21, 2023
FDA Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in R/R AML June 21, 2023
